Concepedia

Author

H. Hausmaninger

Medical University of Vienna

Also Known As

G Steger, H Hausmaninger, H. HAUSMANINGER, H. Hausmaninger, Hubert Hausmaninger

98

Publications

2.9K

Citations

22

H-Index

28

Concepts

All Affiliations

Medical University of ViennaVienna General HospitalUniversity of GrazGraz University HospitalUniversity of Vienna
HH

About

H. Hausmaninger is an author at Medical University of Vienna specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

13

318

2

Health Sciences

5

5

170

3

Immunology

3

3

58

4

Cell Biology

1

1

37

5

Cellular Therapies

1

1

10

H. Hausmaninger

×

36

Publications

2.7K

Citations

22

H-Index

YearCitations

Overexpression of hypoxia-inducible factor 1alpha is associated with an unfavorable prognosis in lymph node-positive breast cancer.

Monika Schindl, Sebastian F. Schoppmann, Hellmut Samonigg,

PubMed

2002

387

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

Michael Gnant, Brigitte Mlineritsch, G. Luschin-Ebengreuth,

Journal of Clinical Oncology

2006

326

Randomized Adjuvant Trial of Tamoxifen and Goserelin Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Evidence for the Superiority of Treatment With Endocrine Blockade in Premenopausal Patients With Hormone-Responsive Breast Cancer—Austrian Breast and Colorectal Cancer Study Group Trial 5

R. Jakesz, H. Hausmaninger, E. Kubista,

Journal of Clinical Oncology

2002

288

Prognostic Value of Lymphangiogenesis and Lymphovascular Invasion in Invasive Breast Cancer

Sebastian F. Schoppmann, Guenther Bayer, Klaus Aumayr,

Annals of Surgery

2004

274

Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial

Gudrun Windbichler, H. Hausmaninger, W. Stummvoll,

British Journal of Cancer

2000

244

Evaluation of the United States Food and Drug Administration-approved scoring and test system of HER-2 protein expression in breast cancer.

P. Birner, Georg Oberhuber, Josefine Stani,

PubMed

2001

184

Clinical Role of Multidrug Resistance Protein 1 Expression in Chemotherapy Resistance in Early-Stage Breast Cancer: The Austrian Breast and Colorectal Cancer Study Group

Martin Filipits, Gudrun Pohl, Margaretha Rudas,

Journal of Clinical Oncology

2005

103

Male breast cancer: Austrian experience

M. Stierer, Harald Rosén, W Weitensfelder,

World Journal of Surgery

1995

85

Comparison of adjuvant therapy with tamoxifen and goserelin vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four-year results of Austrian Breast Cancer Study Group (ABCSG) trial 5

R. Jakesz, H. Hausmaninger, H. Samonigg,

European Journal of Cancer

1999

72

Randomized Trial of Tamoxifen Versus Tamoxifen Plus Aminoglutethimide as Adjuvant Treatment in Postmenopausal Breast Cancer Patients With Hormone Receptor-Positive Disease: Austrian Breast and Colorectal Cancer Study Group Trial 6

Marianne Schmid, R. Jakesz, Hellmut Samonigg,

Journal of Clinical Oncology

2003

59

Page 1